Literature DB >> 15887981

Sentinel lymph node: detection of micrometastases of melanoma in a molecular study.

Valeria C Denninghoff1, Andrea G Kahn, Jorge Falco, Hector P Curutchet, Boris Elsner.   

Abstract

INTRODUCTION: Lymph node status in patients with cutaneous malignant melanoma is the most important prognostic factor. Patients with clinically positive nodes (stage III) should undergo therapeutic lymphadenectomy; however, the surgical approach to the regional disease in patients with negative clinical examination (stage I and II) is still controversial. Selective lymphadenectomy consists of the intraoperative identification of the first node in the nodal basin, the sentinel lymph node (SLN). Routine examination, serial sectioning, and immunohistochemistry may underestimate the presence of tumor cells. PCR is a molecular biology technique that may be useful for the detection of malignant melanoma nodal metastases in the SLN. AIM: The aim of this study was to use tyrosinase messenger RNA (mRNA) amplification for the detection of micrometastases in fresh frozen SLNs.
METHODS: 46 hematoxylin-eosin (HE)-negative sentinel node samples from 42 patients with malignant melanoma were included in this study. Formalin-fixed paraffin-embedded sections were immunostained with S-100 protein and HMB-45. A central portion of the node was submitted for PCR. This method was accomplished with a combination of reverse transcription and amplification of the tyrosinase complementary DNA and double- round PCR (nested reverse transcriptase [RT]-PCR).
RESULTS: In 1 of the 42 SLN-negative patients, immunohistochemistry stains allowed the detection of micrometastases. With molecular biology, 14 of the 42 SLN patients were positive (33%); in another 12 (29%), only the nested RT-PCR was positive. Of the 42 patients, 24 were put into 3 groups and followed for a 5-year period with 1, 7, and 16 patients, respectively, in the groups. The first group involved 1 patient who had provided 2 SLN samples that were found to be SLN-positive using both techniques, immunohistochemistry stains and nested RT-PCR (he had hepatic metastasis and died 24 months after diagnosis). The second group, with only nested RT-PCR positive SLN samples, included 7 of 12 patients who were followed and had a median survival of 37 months; 4 died of widespread metastatic disease, the other 3 patients had event-free survival, but 1 consented to undergo a therapeutic lymphadenectomy as a result of a positive test. The last group consisting of 16 of 32 patients, with complete 5-year survival, who were SLN-negative with both techniques, immunohistochemistry stains and nested RT-PCR. Fourteen of the 16 (88%) were event-free survival during the follow-up, and 2 had local relapse.
CONCLUSION: Tyrosinase mRNA amplification may be a negative prognostic factor for the detection of micrometastases in fresh frozen SLNs using molecular biology techniques.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15887981     DOI: 10.1007/bf03260070

Source DB:  PubMed          Journal:  Mol Diagn        ISSN: 1084-8592


  21 in total

1.  Detection of nodal micrometastases using immunohistochemistry and PCR in melanoma of the arm and trunk.

Authors:  S Boi; P Cristofolini; R Togni; S Girlando; M Camerani; D Donner; M Cristofolini; P Dalla Palma
Journal:  Melanoma Res       Date:  2002-04       Impact factor: 3.599

Review 2.  Immunohistochemistry in the evaluation of melanocytic tumors.

Authors:  D J Ruiter; E B Bröcker
Journal:  Semin Diagn Pathol       Date:  1993-02       Impact factor: 3.464

3.  Detection of microscopic melanoma metastases in sentinel lymph nodes.

Authors:  L L Yu; T J Flotte; K K Tanabe; M A Gadd; A B Cosimi; A J Sober; M C Mihm; L M Duncan
Journal:  Cancer       Date:  1999-08-15       Impact factor: 6.860

4.  Clinical relevance of molecular staging for melanoma: comparison of RT-PCR and immunohistochemistry staining in sentinel lymph nodes of patients with melanoma.

Authors:  W Li; A Stall; S C Shivers; J Lin; F Haddad; J Messina; L F Glass; G Lyman; D S Reintgen
Journal:  Ann Surg       Date:  2000-06       Impact factor: 12.969

5.  Nodal nevi and cutaneous melanomas.

Authors:  K F Carson; D R Wen; P X Li; A M Lana; C Bailly; D L Morton; A J Cochran
Journal:  Am J Surg Pathol       Date:  1996-07       Impact factor: 6.394

6.  Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma.

Authors:  J E Gershenwald; M I Colome; J E Lee; P F Mansfield; C Tseng; J J Lee; C M Balch; M I Ross
Journal:  J Clin Oncol       Date:  1998-06       Impact factor: 44.544

Review 7.  The role of elective lymph node dissection in melanoma: rationale, results, and controversies.

Authors:  C M Balch
Journal:  J Clin Oncol       Date:  1988-01       Impact factor: 44.544

8.  Lymph node micrometastases of cutaneous melanoma: increased sensitivity of molecular diagnosis in comparison to immunohistochemistry.

Authors:  H J Blaheta; B Schittek; H Breuninger; E Maczey; S Kroeber; K Sotlar; U Ellwanger; M H Thelen; G Rassner; B Bültmann; C Garbe
Journal:  Int J Cancer       Date:  1998-08-21       Impact factor: 7.396

9.  Accurate molecular detection of melanoma nodal metastases: an assessment of multimarker assay specificity, sensitivity, and detection rate.

Authors:  V Davids; S H Kidson; G S Hanekom
Journal:  Mol Pathol       Date:  2003-02

10.  Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma.

Authors:  X Wang; R Heller; N VanVoorhis; C W Cruse; F Glass; N Fenske; C Berman; J Leo-Messina; D Rappaport; K Wells
Journal:  Ann Surg       Date:  1994-12       Impact factor: 12.969

View more
  2 in total

1.  Use of indocyanine green for detecting the sentinel lymph node in breast cancer patients: from preclinical evaluation to clinical validation.

Authors:  Chongwei Chi; Jinzuo Ye; Haolong Ding; De He; Wenhe Huang; Guo-Jun Zhang; Jie Tian
Journal:  PLoS One       Date:  2013-12-16       Impact factor: 3.240

Review 2.  Issues affecting molecular staging in the management of patients with melanoma.

Authors:  G Palmieri; M Casula; M C Sini; P A Ascierto; A Cossu
Journal:  J Cell Mol Med       Date:  2007 Sep-Oct       Impact factor: 5.310

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.